Deoxyribonucleic acid in donor nucleated cells (Donor DNA)

DNA in donor T lymphocytes and other nucleated donor cells is the primary molecular target for interventions designed to prevent Transfusion-Associated Graft-versus-Host Disease (TA-GvHD). In this condition, viable donor T-cells recognize the recipient's tissues as foreign and mount a systemic immune attack, which is often fatal (StatPearls, 2023, https://www.ncbi.nlm.nih.gov/books/NBK470573/). The biological function of this DNA in the context of transfusion is to facilitate the proliferation and activation of donor T-cells upon exposure to the recipient's alloantigens. Therapeutic interventions such as gamma irradiation or Pathogen Reduction Technologies (PRT) like the INTERCEPT Blood System (using amotosalen) or Mirasol (using riboflavin) specifically target this DNA to induce covalent cross-links or oxidative damage (FDA, 2014, https://www.fda.gov/media/89930/download; Terumo BCT, 2021). These modifications render the DNA template-incompetent, effectively blocking the cell cycle and preventing the clonal expansion of donor leukocytes while preserving the physiological function of non-nucleated cells like erythrocytes and platelets (Journal of Blood Medicine, 2016, https://doi.org/10.2147/JBM.S70209). Consequently, the donor T-cells cannot mount an effective immune response, thereby mitigating the risk of GvHD in susceptible, immunocompromised patients.

Other names

DNA in donor T lymphocytesDonor leukocyte DNAAllogeneic T-cell DNAGenomic DNA of donor nucleated cells

Induction of irreversible DNA damage, such as interstrand cross-linking or double-strand breaks, which prevents the replication and clonal expansion of donor T-lymphocytes (PubMed, PMID: 25563000; FDA, https://www.fda.gov/media/89930/download).